Memantine ratiopharm



This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Memantine ratiopharm. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the European Union and its conditions of use. It is not intended to provide practical advice on how to use Memantine ratiopharm.

For practical information about using Memantine ratiopharm, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 30/06/2022

Authorisation details

Product details
Memantine ratiopharm
Agency product number
Active substance
memantine hydrochloride
International non-proprietary name (INN) or common name
Therapeutic area (MeSH)
Alzheimer Disease
Anatomical therapeutic chemical (ATC) code

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Ratiopharm GmbH
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Graf-Arco-Str. 3
D-89079 Ulm

Product information

03/06/2022 Memantine ratiopharm - EMEA/H/C/002671 - N/0023

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.


Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group


Therapeutic indication

Treatment of patients with moderate to severe Alzheimer’s disease

Assessment history

How useful was this page?

Add your rating
1 rating